$ILMN

Meister Keith A. sold $1.9M of ILMN (indirect holdings)

Meister Keith A. sold 11,760 indirectly-held shares of ILLUMINA, INC. (ILMN) at $159.57 ($1.88M total) on 2026-05-29.

Original reporting
SEC EDGAR · Meister Keith A.
Published Jun 1, 2026, 10:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 1, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ILMN
Neutral
medium confidence
Mentioned
$ILMN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNNeutralLow
01

Why it matters

The key tradable element is the disclosed sale size (~$1.88M) and the absence of a pre-arranged 10b5-1 plan, which can modestly influence short-term sentiment.

02

Market read

A director sold shares at ~$159.57; traders may monitor for follow-on insider activity or corroborating fundamental news.

03

What to watch

No 10b5-1 plan is noted, but the filing does not state motive, tax needs, or diversification targets; insider sales often have non-informational drivers.

Relevance 6/10Novelty 6/10Timing: Filed June 1, covering a sale executed May 29

Background

This is an SEC Form 4 insider transaction disclosure for Illumina (director role).

Company-level read

Ticker impact

$ILMNNeutralMedium confidence
Context

Illumina director Keith A. Meister sold 11,760 shares in an open-market transaction disclosed via SEC Form 4.

Expected impact

Low near-term impact; any reaction is likely sentiment-driven and typically fades unless paired with other company news.

Evidence & confidence

The filing provides a specific sale price/value and confirms it was not under a pre-arranged 10b5-1 plan, but it does not include new operational/financial information.

Market effects

Limited read-through to biotech/life-science tools; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity/portfolio management; without additional context, it may not signal reduced confidence.

Key entities

  • Illumina, Inc.

    Issuer of the securities sold by a director; subject of the insider transaction disclosure.

  • Keith A. Meister

    Director who executed an open-market sale of ILMN shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ILMNHighAI 8/10

Illumina Q2FY26 Results: Revenue up 9.5% to $1.16 billion

Illumina reported Q2 2026 revenue of $1.16B, up 9.5% YoY, driven by NovaSeq X demand and clinical consumables growth. Non-GAAP EPS rose 10% to $1.31. The company raised full-year guidance, projecting revenue of $4.60B-$4.64B and EPS of $5.30-$5.40. Management cited strong instrument placements and cost management despite rising expenses. Illumina repurchased 0.9M shares and holds $1.17B in cash. The stock has returned 13.26% annually over 20 years, outperforming the market by 3.84%.

$ILMNHighAI 8/10

Illumina Reports Q2 2026 Results: Full Earnings Call Transcript - Illumina (NASDAQ:ILMN)

Illumina (ILMN) reported Q2 2026 revenue growth of 9.5% YoY and EPS growth of 10%, driven by strong demand for NovaSeq X. The company raised its 2026 guidance, expecting full-year organic revenue growth over 5% and mid-teens growth in clinical consumables. Strategic initiatives include expanding multi-omics capabilities and strengthening the BioInsight platform. Management emphasized cost management and confidence in long-term targets.

$BELow

Three Stocks Are Joining the S&P 500. Will They Actually Improve VOO’s Returns?

Vanguard S&P 500 ETF (VOO) will add Bloom Energy (BE), Illumina (ILMN), and another company, while removing Molson Coors (TAP), The Trade Desk (TTD), and Builders FirstSource (BLDR). BE's product revenue surged 215% due to AI demand, and ILMN raised EPS guidance. The changes have minimal impact on VOO's returns, as the fund is heavily concentrated in megacap stocks.

$ILMNHigh

Illumina Stock Climbs As Analyst Upgrades Meet S&P 500 Boost

Illumina Inc. (ILMN) shares rose 7.15% on September 15, 2026, after UBS upgraded it to Buy with a $260 price target, and Argus raised its target to $235. The company's Q2 revenue was $1.16B, with EBITDA of $354M. Illumina is also being added to the S&P 500, effective September 21, 2026, which may drive further demand. The stock trades at a P/E ratio of 38 and P/S ratio of 6.9, reflecting its growth prospects. Analysts cite revenue reacceleration, margin expansion, and clinical demand as key driv